Protalix BioTherapeutics (PLX) News Today $2.84 +0.11 (+4.03%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$2.86 +0.02 (+0.53%) As of 05/7/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock PLX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025May 6 at 5:10 PM | seekingalpha.comEquities Analysts Offer Predictions for PLX Q1 EarningsProtalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of Protalix BioTherapeutics in a note issued to investors on Monday, April 28th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post eaMay 3, 2025 | marketbeat.comRenaissance Technologies LLC Buys 162,100 Shares of Protalix BioTherapeutics, Inc. (NYSE:PLX)Renaissance Technologies LLC grew its stake in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) by 17.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,118,000 shares of the company's sApril 28, 2025 | marketbeat.comProtalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising PipelineApril 10, 2025 | seekingalpha.comProtalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025March 24, 2025 | finance.yahoo.comIs Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?March 22, 2025 | msn.comProtalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMIMarch 21, 2025 | proactiveinvestors.comZacks Small Cap Issues Pessimistic Estimate for PLX EarningsProtalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Equities researchers at Zacks Small Cap dropped their FY2025 earnings per share estimates for Protalix BioTherapeutics in a research note issued on Tuesday, March 18th. Zacks Small Cap analyst J. Vandermosten now forecasts that the companyMarch 21, 2025 | marketbeat.comProtalix Stock (PLX) Grabbing Attention with Record Revenue SurgeMarch 20, 2025 | markets.businessinsider.comProtalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.comStockNews.com cut Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday.March 20, 2025 | marketbeat.comProtalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | seekingalpha.comEarnings call transcript: Protalix Q4 2024 sees 31% revenue growthMarch 19, 2025 | uk.investing.comAmended: Protalix Annual Earnings FallMarch 19, 2025 | nasdaq.comProtalix plans Phase 2 for PRX-115 in H2 2025, projects higher royalty revenues by 2030March 19, 2025 | seekingalpha.comProtalix Biotherapeutics gains momentum: analysts see long-term upsideMarch 18, 2025 | proactiveinvestors.comProtalix Biotherapeutics gains momentum: analysts see long-term upsideMarch 18, 2025 | proactiveinvestors.comProtalix BioTherapeutics (AMEX:PLX) Stock, Short Interest ReportMarch 18, 2025 | benzinga.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2024 Earnings Call TranscriptMarch 18, 2025 | msn.comPLX: 2024 ResultsMarch 18, 2025 | msn.comProtalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidateMarch 18, 2025 | proactiveinvestors.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business ResultsMarch 17, 2025 | finanznachrichten.deProtalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And BeyondMarch 17, 2025 | benzinga.comProtalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business ResultsMarch 17, 2025 | prnewswire.comProtalix BioTherapeutics Q4 Earnings PreviewMarch 16, 2025 | msn.comProtalix BioTherapeutics (NYSE:PLX) Upgraded by StockNews.com to Strong-Buy RatingStockNews.com upgraded shares of Protalix BioTherapeutics from a "buy" rating to a "strong-buy" rating in a research note on Wednesday.March 13, 2025 | marketbeat.comProtalix BioTherapeutics (NYSE:PLX) Trading Down 2.1% - What's Next?Protalix BioTherapeutics (NYSE:PLX) Stock Price Down 2.1% - Here's WhyMarch 1, 2025 | marketbeat.comProtalix Biotherapeutics poised for profitability as rare disease drug gains momentumFebruary 24, 2025 | proactiveinvestors.comZacks Small Cap Has Bearish Outlook for PLX FY2025 EarningsProtalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Investment analysts at Zacks Small Cap reduced their FY2025 earnings per share estimates for shares of Protalix BioTherapeutics in a research note issued on Monday, February 3rd. Zacks Small Cap analyst J. Vandermosten now anticipates thatFebruary 5, 2025 | marketbeat.comFY2024 Earnings Estimate for PLX Issued By HC WainwrightProtalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Protalix BioTherapeutics in a report issued on Monday, February 3rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of $0.01February 5, 2025 | marketbeat.comProtalix Biotherapeutics gains momentum in the rare disease space: analystsFebruary 4, 2025 | proactiveinvestors.comResearch Analysts Offer Predictions for PLX Q1 EarningsProtalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Protalix BioTherapeutics in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst R. Selvaraju forecFebruary 4, 2025 | marketbeat.comProtalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor ConferenceFebruary 4, 2025 | prnewswire.comProtalix price target raised to $15 from $10 at H.C. WainwrightFebruary 4, 2025 | markets.businessinsider.comH.C. Wainwright lifts Protalix stock target to $15, maintains buyFebruary 4, 2025 | msn.comPLX: Revisiting the ThesisFebruary 4, 2025 | finance.yahoo.comProtalix BioTherapeutics (NYSE:PLX) Given New $15.00 Price Target at HC WainwrightHC Wainwright increased their price objective on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a "buy" rating in a report on Monday.February 3, 2025 | marketbeat.comProtalix BioTherapeutics (NYSE:PLX) Lowered to "Buy" Rating by StockNews.comStockNews.com cut shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday.January 24, 2025 | marketbeat.comJane Street Group LLC Has $47,000 Position in Protalix BioTherapeutics, Inc. (NYSE:PLX)Jane Street Group LLC lessened its stake in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) by 84.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 45,952 shares of the company's stock after selling 244,307 shares duJanuary 16, 2025 | marketbeat.comChiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfaDecember 9, 2024 | prnewswire.comPLX: Self-Sustaining Rise to Lead in Renal Rare DiseaseNovember 15, 2024 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | insidermonkey.comProtalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ...November 15, 2024 | finance.yahoo.comProtalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business ResultsNovember 14, 2024 | finanznachrichten.deEarnings Outlook For Protalix BioTherapeuticsNovember 13, 2024 | benzinga.comProtalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024October 25, 2024 | finance.yahoo.comOTC Markets Hosts Virtual Investor Presentation with Dror Bashan, President & CEO of Protalix Biotherapeutics, and John Vandermosten, Senior Analyst at Zacks SCROctober 24, 2024 | msn.comProtalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024September 16, 2024 | globenewswire.comProtalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | tmcnet.comProtalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory NotesSeptember 3, 2024 | prnewswire.com Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address PLX Media Mentions By Week PLX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PLX News Sentiment▼1.040.64▲Average Medical News Sentiment PLX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PLX Articles This Week▼51▲PLX Articles Average Week Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Spyre Therapeutics News Mineralys Therapeutics News Intellia Therapeutics News Nurix Therapeutics News Gyre Therapeutics News Arcus Biosciences News Collegium Pharmaceutical News Avadel Pharmaceuticals News Vir Biotechnology News Anavex Life Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:PLX) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | Sponsored270x more lucrative than NVIDIA???270x more lucrative than NVIDIA??? If you've missed out on NVIDIA's recent 1,600% run... Don't worry. ...Behind the Markets | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was d...Investors Alley | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredUrgent News from my Oceanfront Estate Near Mar-a-LagoFor 40 years, I've had a front-row seat to history's greatest wealth creation events. I spotted Microsoft a...InvestorPlace | SponsoredElon’s Been UpgradedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLX Stock Free PLX Stock Alerts